26 February 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Ondine Biomedical Strengthens Leadership Team with the Appointment of Michael Behlke as non-Board CFO & COO

Ondine Biomedical Inc. (LON: OBI), a global leader in light-activated antimicrobial treatments, is pleased to announce the appointment of Michael S. Behlke as Chief Financial Officer (CFO) and Chief Operating Officer (COO), effective immediately. Recognized in the US MedTech community for his career achievements, Mr. Behlke brings over 30 years of financial and operational leadership experience, positioning Ondine for accelerated growth and commercialization success.

Mr. Behlke's distinguished career includes securing over $250 million in funding, supporting acquisitions exceeding $700 million, and driving commercialization strategies for emerging and mid-stage medical companies. Prior to joining Ondine, he served as CFO and Acting COO at Ventec Life Systems with full P&L responsibility, where he played a critical role in scaling the company's revenue from $13 million to $500 million annually and in its landmark partnership with General Motors to rapidly scale up and manufacture ventilators for the US Strategic National Stockpile during the COVID-19 pandemic.

Carolyn Cross, Ondine's Chief Executive Officer:

"We are thrilled to welcome Michael to our leadership team. Ondine is at a critical inflection point as we expand our hospital-based infection prevention solutions. Michael's extensive MedTech industry experience, operational leadership, and business transformation successes will be key to accelerating our worldwide commercialization efforts, initially within Canada and the UK/EU, and then rapidly expanding into the U.S. post-FDA approval."

In his new role, Mr. Behlke will oversee Ondine's capital markets strategies, operational efficiency, and international expansion, ensuring the company's is well-positioned for sustained growth and market leadership. His deep expertise in P&L management, business transformation, and supply chain execution will be key to advancing Ondine's mission of revolutionizing infection prevention through its photodisinfection-based platform technology.

Michael Behlke, CFO & COO of Ondine Biomedical:

"I am honored to join Ondine at this pivotal moment. The company's groundbreaking photodisinfection technology represents a paradigm shift in infection control. I look forward to working with this talented team to drive operational excellence, financial growth, and global adoption of this life-saving technology."

This appointment strengthens Ondine's leadership team and underscores the Company's commitment to expanding its footprint in key global markets and addressing the urgent need for innovative antimicrobial solutions in healthcare settings.

Enquiries:

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection') to prevent and treat infections, including those caused by antibiotic-resistant bacteria. Ondine's patented light-activated antimicrobial technology offers a safe, rapid, and effective alternative to traditional antibiotics, tackling some of the most pressing healthcare challenges today.